Maximizing value across drug development: Embracing a new CDMO and CRO partnership approach

Join us to explore how these partnerships can drive success in today's demanding pharmaceutical landscape.

Pharmaceutical and biotech companies are navigating a complex landscape marked by heightened competition and rising costs. The push for faster innovation and a shorter time to market is met with internal pressures, including increased R&D expenses and constrained funding. As a result, organizations are rethinking their approach to drug development, with a focus on maximizing value and efficiency at every stage.

In this webinar, we will present key insights from preliminary findings by the TUFTS Center for the Study of Drug Development, exploring how a comprehensive model that brings CDMO and CRO services under one roof can significantly impact the expected Net Present Value (eNPV) of drug development programs. We will demonstrate how streamlined services across drug substance, drug product, and clinical research can enhance efficiency, reduce timelines, and ultimately deliver high-quality therapies to patients faster.

Key takeaways include:

• The financial and operational benefits of leveraging eNPV modeling for combined CDMO and CRO services.
• Practical strategies for simplifying the development journey with Thermo Fisher Scientific’s Accelerator™ Drug Development.
• Case studies showcasing real-world successes of biotech and biopharma companies in accelerating their path from lab to patient.